1.World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: World Health Organization. Available via https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ Accessed 2020-07-28.
2.https://cdafound.org/dashboard/polaris/dashboard.htmls
3.Miao Z, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1677-1687.
4.Blach S, et al. Global Status Update On the HCV Prevalence and Cascade of Care Entering 2020. AASLD 2021. Oral 100.
5.陈雨欣,吴超.中国丙型病毒性肝炎院内筛查管理流程(试行).中华肝脏病杂志,2020,28(10):820-823.
6.Ji P, et al. Real-World Effectiveness and Safety of Interferon-Free DAAS for 14,676 Hepatitis C (CHC) Patients with Genotypes 1, 2, 3, 4 And 6: A Multinational Study. AASLD 2021. Poster 947.
7.Yue W，et al. Efficacy and Safety of 12 Weeks of Sofosbuvir/Velpatasvir with or Without Ribavirin in Genotype 3 Hepatitis C Virus-Infected Patients: A Realworld Study of China and Safety of 12 Weeks of Sofosbuvir/Velpatasvir with or Without Ribavirin in Genotype 3 Hepatitis C Virus-Infected Patients: A Real-World Study of China. AASLD 2021. Poster 960.
8.Wang D，et al. Efficacy and Safety of Sofosbuvir/Velpatasvir in Genotype 3 And 6 HCV Patients in East China. AASLD 2021. Poster 961.
9.Yu L，et al. Safety and Effectiveness of Sofosbuvir/Velpatasvir Treatment in Chinese Chronic Hepatitis C Patients Undergoing Hemodialysis: A Single-Center Prospective Study. AASLD 2021. Poster 985.
10.Peng H，et al. Identifying Barriers to Treat HCV in DAA Era Among Healthcare Providers in Guizhou Province of China: A Cross-Sectional Survey. AASLD 2021. Poster 2160.
11.Huang C, et al. A Comprehensive People-Centered Outreach Healthcare System Targeting HCV Micro-Elimination in Hyperendemic Areas of Taiwan (Compact) – Establishment of A Model Toward HCV Elimination. AASLD 2021. Poster 920.
12.Su W, et al. Community-Based Multi-Faceted Approaches for Hepatitis C Elimination in Marginalized Population of Changhua County Taiwan. AASLD 2021. Poster 954.
13.Liu H, et al. Prevalence and Clinical Characteristics of Hepatitis D in Southwest of China. AASLD 2021. Poster 699.
14.Jacobson I, et al. Higher Baseline Comorbidities and Liver Complications Among Patients with Hepatitis Delta Infection Versus Hepatitis B Monoinfection: A National Us Claims Database Analysis. AASLD 2021. Poster 695.
15.Allweiss L, et al. Strong Intrahepatic Decline of Hepatitis D Virus RNA and Antigen After 48 Weeks of Treatment with Bulevirtide in Chronic HBV/HDV Co-Infected Patients: Interim Results from A Multicenter, Open-Label, Randomized Phase 3 Clinical Trial (MYR301) AASLD 2021. Oral 223.
